Spartha Medical receives €2.4m investment

Spartha Medical, a French medtech company specialised in developing multifunctional antimicrobial, antiviral and anti-inflammatory coatings, has received €2.4 million ($2.75 million) in grants and an additional undisclosed equity financing from the European Innovation Council (EIC) Fund. 

The company’s coatings for medical devices offer antimicrobial, antiviral and anti-inflammatory capabilities – including against SARS-CoV-2. Spartha’s innovation is a non-antibiotic-based solution, derived from natural biopolymers that make it biocompatible and applicable to all surface types. The antibacterial effect occurs by contact on the polymer coated surfaces. The coating can be used on medical devices without affecting their primary function.

Dr Nihal Engin Vrana, CEO of Spartha Medical, said: "Spartha Medical is thrilled to have the support of the EIC fund, which we will use to launch clinical trials, strengthen our infrastructure and hire new talent. We are set to achieve the necessary regulatory compliance steps, including ISO certification, as well as start researching the next generation of coatings. These will propel us to the forefront in preventing post-operative infections and in fighting against resistant bacteria. By consolidating our current co-development programs and partnerships and the development of new business opportunities, our aim is to become the market leader in customised coating development services, using a platform supported by Artificial Intelligence."